<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00130702</url>
  </required_header>
  <id_info>
    <org_study_id>05-086</org_study_id>
    <nct_id>NCT00130702</nct_id>
  </id_info>
  <brief_title>Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia</brief_title>
  <official_title>A Phase II Study of Iressa (Gefitinib), in Patients With Relapsed or Refractory Acute Myelogenous Leukemia and in Older Patients With Newly Diagnosed Acute Myelogenous Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Childrenâ€™s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how effective, and to what extent, Iressa is in the
      treatment of acute myelogenous leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive Iressa daily until either disease progression or intolerable toxicity
      develops. On Day 1 of treatment, a physical exam and bloodwork will be performed. Once weekly
      for the first 8 weeks, a physical exam and complete blood count with differential will be
      performed.

      For the first year, a physical exam, bloodwork will be performed monthly. Bone marrow
      biopsies will be performed after the first month of therapy and then every 3 months for the
      first year. After the first year a physical exam, bloodwork will be performed every 3 months
      and bone marrow biopsies every 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the response rate of Iressa in patients with acute myelogenous leukemia</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the safety of Iressa in patients with acute myelogenous leukemia</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to determine the biologic activity of Iressa in patients with acute myelogenous leukemia</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Myelogenous Leukemia, Acute</condition>
  <arm_group>
    <arm_group_label>Gefitinib (Iressa)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive Gefitinib (Iressa) at a dose of 750 mg orally (three 250 mg tabs) each day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
    <description>gefitinib (Iressa) at a dose of 750 mg, once per day</description>
    <arm_group_label>Gefitinib (Iressa)</arm_group_label>
    <other_name>Iressa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have pathologically documented acute myelogenous leukemia and either not
             be a candidate for myelosuppressive chemotherapy due to age or comorbid disease; or
             have relapsed acute myelogenous leukemia or be refractory to standard therapy and not
             likely to require cytoreductive therapy within 30 days.

          -  ECOG performance status 0, 1 or 2

          -  Age &gt; 18 years

          -  Adequate kidney and hepatic function

          -  Greater than 4 weeks from any chemotherapy, radiotherapy, immunotherapy, or systemic
             steroid therapy with the exception of hydroxyurea.

          -  Greater than 2 months following bone marrow or peripheral blood stem cell
             transplantation or donor lymphocyte infusion.

        Exclusion Criteria:

          -  Uncontrolled active infection

          -  Urgent need for cytoreductive chemotherapy, surgery, or radiotherapy

          -  Current chemotherapy or chemotherapy within the last 4 weeks.

          -  Pregnancy or nursing mothers

          -  Infection with HIV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel J DeAngelo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2005</study_first_submitted>
  <study_first_submitted_qc>August 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2005</study_first_posted>
  <last_update_submitted>April 29, 2014</last_update_submitted>
  <last_update_submitted_qc>April 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Daniel J. DeAngelo, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>acute myelogenous leukemia</keyword>
  <keyword>gefitinib</keyword>
  <keyword>Iressa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

